# Azacitidine (AZA) in Minimal Residual Disease (MRD) Chronic Myeloid Leukemia (CML)

> **NCT01460498** · PHASE1 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 3 (actual)

## Conditions studied

- Leukemia

## Interventions

- **DRUG:** Azacitidine (AZA)
- **DRUG:** Tyrosine kinase inhibitor (TKI)
- **DRUG:** Azacitidine

## Key facts

- **NCT ID:** NCT01460498
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-08-08
- **Primary completion:** 2019-08-07
- **Final completion:** 2019-08-07
- **Target enrollment:** 3 (ACTUAL)
- **Last updated:** 2020-03-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01460498

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01460498, "Azacitidine (AZA) in Minimal Residual Disease (MRD) Chronic Myeloid Leukemia (CML)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01460498. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*